Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Conditions
Interventions
Etrasimod
Placebo
Locations
315
United States
Digestive Health Specialists of the Southeast
Dothan, Alabama, United States
Arizona Digestive Health
Sun City, Arizona, United States
Om Research, LLC
Lancaster, California, United States
Entertainment Medical Group, Inc.
Los Angeles, California, United States
United Medical Doctors
Murrieta, California, United States
San Diego Gastroenterology Medical Associates
San Diego, California, United States
Start Date
June 13, 2019
Primary Completion Date
February 8, 2022
Completion Date
February 16, 2022
Last Updated
December 20, 2022
NCT06372613
NCT07550673
NCT07374471
NCT06071312
NCT05739864
NCT04338204
Lead Sponsor
Arena Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions